This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Peak Bio Valuation

Is PKBO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PKBO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PKBO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PKBO's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PKBO?

Key metric: As PKBO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for PKBO. This is calculated by dividing PKBO's market cap by their current revenue.
What is PKBO's PS Ratio?
PS Ratio	6.9x
Sales	US$75.19k
Market Cap	US$1.62m

PKBO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	138.7x
Enterprise Value/EBITDA	-1.7x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does PKBO's PS Ratio compare to its peers?

The above table shows the PS ratio for PKBO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	4.1x
TRVN Trevena	2.8x	-6.1%	US$1.5m
RGBP Regen BioPharma	3.3x	n/a	US$841.3k
VYNT Vyant Bio	3.1x	n/a	US$1.1m
AXIM AXIM Biotechnologies	7.1x	n/a	US$657.1k
PKBO Peak Bio	6.9x	n/a	US$1.6m

Price-To-Sales vs Peers: PKBO is expensive based on its Price-To-Sales Ratio (6.9x) compared to the peer average (5.4x).

Price to Sales Ratio vs Industry

How does PKBO's PS Ratio compare vs other companies in the US Biotechs Industry?

126 Companies	Price / Sales	Estimated Growth	Market Cap
BIIB Biogen	2.4x	1.3%	US$23.13b
MRNA Moderna	3.2x	6.7%	US$16.80b
INCY Incyte	3.5x	9.0%	US$14.16b
ALKS Alkermes	3.1x	-0.7%	US$4.75b

126 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: PKBO is good value based on its Price-To-Sales Ratio (6.9x) compared to the US Biotechs industry average (12x).

Price to Sales Ratio vs Fair Ratio

What is PKBO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PKBO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	6.9x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate PKBO's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

5.3%

17.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$204.02

6.8%

-3.2%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.79

5.4%

19.1%